CD19 and lymphoma: Four different commercially-available CD19 auto-CARs are currently approved by the U.S. Food and Drug Administration (FDA) for r/r lymphomas: axi-cel (KTE-019), tisa-cel (CTL019), liso-cel (JCAR017) and brexu-cel (KTE-X19) [4], based on results of ZUMA-1 [5], JULIET [6], TRANSCEND [7] and ZUMA-2 [8], respectively (Table 1).